Streetbeat News

Products Services

SYBX

The World Health Organization's International Nonproprietary Names Expert Committee has chosen Labafenogene Marselecobac as the nonproprietary name for Synlogic's investigational drug for Phenylketonuria, previously known as SYNB1934.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 11:17 am

COYA

Coya Therapeutics has announced the presentation of results from an academic clinical study in patients with Alzheimer's disease with subcutaneous ld IL-2 at the 2023 Alzheimer's Association International Conference scheduled in July.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 11:15 am

WGS

GeneDx, a genetic testing company, has announced that it will present new data on urine mitochondrial DNA testing at the 2023 United Mitochondrial Disease Foundation's Mitochondrial Medicine Symposium in North Carolina.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 11:13 am

FHTX

Foghorn Therapeutics has announced plans to discontinue the development of FHD-286 for Uveal Melanoma. However, the company maintains that Phase 1 trial data supports the safety and tolerability profile of FHD-286.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 11:12 am

ORCL

Oracle has announced the addition of generative artificial intelligence features to its human resources software for businesses.

Portfolio Pulse from Charles Gross

June 28, 2023 | 11:09 am

LUCY

Innovative Eyewear has announced a new retail partnership with PRIVATO Duty-free to create Lucyd Eyewear retail showcases in seven of its airport-based locations. The complete roll-out is expected in Q3 2023.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 11:08 am

MSFT

A developer has created WinGPT, a ChatGPT client that can run on the Windows 3.1 operating system. The developer, who previously launched Windle, a Windows 3.1 app for the word game Wordle, faced challenges due to the severe memory limitations of Windows 3.1 and 386-based computers. Microsoft is also planning to integrate ChatGPT into Windows 11.

Portfolio Pulse from Rounak Jain

June 28, 2023 | 11:06 am

FWBI

First Wave BioPharma has dosed the final patient in the Phase 2 SPAN trial of Adrulipase for Exocrine Pancreatic Insufficiency in patients with Cystic Fibrosis. The trial uses an enhanced enteric microgranule delivery formulation. Topline results are expected by mid-2023.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 11:05 am

CGTX

Cognition Therapeutics announced positive topline results from its Phase 2 SEQUEL study of CT1812 in 16 adults with mild-to-moderate Alzheimer's disease, meeting its primary endpoints for safety and tolerability.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 11:03 am

ETON

The FDA has issued a complete response letter to Eton Pharmaceuticals' marketing application for its dehydrated alcohol injection for methanol poisoning. The issues raised are primarily related to chemistry manufacturing and controls.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 10:52 am